The majority of gastrointestinal stromal tumors (GISTs) are driven by oncogenic KIT signaling and can therefore be effectively treated with the tyrosine kinase inhibitor (TKI) imatinib mesylate. However, most GISTs develop imatinib resistance through secondary KIT mutations. The type of resistance mutation determines sensitivity to approved second-/third-line TKIs but can show high inter-and intratumoral heterogeneity.
INTRODUCTION
The majority of gastrointestinal stromal tumors (GISTs) are driven by an oncogenic mutation that constitutively activates the KIT or PDGFRA (platelet-derived growth factor receptor alpha) receptor tyrosine kinase. This leads to ligand-independent activation of the receptor as well as downstream signaling cascades that promote tumor cell proliferation and survival. The tyrosine kinase inhibitor (TKI) imatinib mesylate (Gleevec®) is a highly effective first-line drug for the treatment of inoperable or metastatic GIST.
Nevertheless, there is a need for new therapeutic approaches, because resistance to imatinib develops in approximately 50% of patients within the first two years of treatment 1 . In this scenario, the FDA-approved second-and third-line drugs sunitinib and regorafenib offer little additional benefit 2 .
The major mechanism of TKI resistance in GIST involves secondary mutations in the kinase domain of the primarily affected kinase indicating the continued dependency on KIT/PDGFRA kinase activation. Therefore, therapeutic strategies targeting these kinases without the need of kinase domain binding seem particularly promising.
The 26S proteasome is a 2.5 MDa multiprotein complex and the main protein degradation machinery of eukaryotic cells 3 . It consists of a 20S tube-like proteolytic core particle and two 19S regulatory particles at either end. Proteins destined to be degraded are selectively targeted to the proteasome by the addition of a series of covalently attached ubiquitin molecules. Deubiquitinating enzymes associated with the 19S regulatory subunit remove these ubiquitin chains before proteins can enter the proteolytic subunit. The 20S core contains three major proteolytic activities (β5 chymotrypsin-like, β1 caspase-like and β2 trypsin-like), which together yield peptides that are three to 25 amino acids in length. Inhibitors of the 20S proteasome core particle, such as the prototype proteasome inhibitor bortezomib (Velcade®), have gained clinical importance for the treatment of multiple myeloma and certain lymphomas 4 .
Previous studies from our laboratory have shown that targeting the ubiquitinproteasome machinery with bortezomib is highly effective in GIST cells. Importantly, this was independent of KIT mutational status 5 . We could demonstrate that bortezomibinduced apoptosis is mediated by a dual mechanism of action. Inhibition of the proteolytic machinery leads to increased levels of soluble, non-chromatin-bound pro-apoptotic histone H2AX [5] [6] [7] . In addition, a dramatic downregulation of KIT expression is mediated by inhibition of active gene transcription 5 . It is known that loss of KIT expression, e.g. via siRNA-mediated knockdown or HSP90 inhibition, is a strong inducer of apoptosis in GIST cells 6, 8 . Although bortezomib has not shown significant clinical activity in many solid tumors, including an array of sarcomas 9 , there are a number of recent reports of bortezomib's clinical activity in GIST. For example, a GIST patient had the most significant response, an approximately 36% tumor shrinkage (WHO criteria), in a study evaluating bortezomib as a daily subcutaneous regimen in various solid tumors 10 . In another study testing bortezomib in combination with vorinostat, one of the two GIST patients included in the cohort achieved stable disease (SD) 11 . Nevertheless, bortezomib is associated with marked adverse effects, warranting the evaluation of second-generation proteasome inhibitors 10, 12 .
Carfilzomib (Kyprolis®, PR-171), ixazomib (Ninlaro®, MLN-9708), and delanzomib (CEP-18770) are inhibitors of the 20S proteolytic core particle of the 26S proteasome, like bortezomib 4 . Carfilzomib is an intravenously administered tetrapeptide epoxyketone that differs structurally and mechanistically from bortezomib 13 . Approved by the FDA in 2012 for therapy-resistant multiple myeloma 14 , it inhibits the β5 chymotrypsin-like subunit of the proteasome, similar to bortezomib, but does so irreversibly and with a higher selectivity 13 .
Together with the notion that carfilzomib has less off-target effects, these facts may explain its efficacy in bortezomib-resistant cells as well as a lesser degree of adverse effects 13, 15 . Ixazomib is the first orally bioavailable inhibitor of the 20S proteasome 16 . It is a structural derivative of bortezomib with improved pharmacologic properties and reversibly inhibits the chymotrypsin-like β5 subunit of the 20S proteasome [14] [15] [16] . Ixazomib was recently approved for the treatment of multiple myeloma 17 . Delanzomib is a reversible P2 threonine boronic acid proteasome inhibitor that can be administered orally and intravenously 18, 19 . It potently inhibits the β5 chymotrypsin-like and the β1 caspase-like subunit of the proteasome. Compared to bortezomib, delanzomib exhibits a more sustained inhibition of proteasome activity in multiple myeloma cells 18, 19 . Results of a phase I/II clinical trial in relapsed and refractory multiple myeloma were recently reported 20, 21 .
In addition to inhibitors of the proteolytic 20S core of the proteasome, several regulators of the proteasomal degradation process have recently emerged as therapeutic targets. Deubiquitinase enzymes (DUBs) catalyze the cleavage of ubiquitin from proteasome-targeted, ubiquitin-conjugated proteins at the 19S regulatory core particle of the 26S proteasome 3 . b-AP15 is a DUB inhibitor that interferes with the activity of the ubiquitin-specific peptidase 14 (USP14) and ubiquitin carboxyl-terminal hydrolase isozyme L5 (UCHL5) 21, 22 . As a result, b-AP15 leads to rapid accumulation of high molecular weight ubiquitin conjugates, triggering a functional shutdown of the proteasome 22 . Importantly, b-AP15 has shown pre-clinical activity in multiple myeloma and Waldenström's macroglobulinaemia 23, 24 .
A second important regulatory process of the proteolytic machinery involves the small ubiquitin-like modifier NEDD8 25 . NEDD8 is attached to lysine residues of proteins in a similar fashion as ubiquitin, and "neddylation" has been specifically implicated in regulating the turnover of cell cycle-regulatory proteins, such as p27 Kip1 26, 27 . Neddylation of the cullin subunits of cullin-based E3 ubiquitin ligases is critical for the recruitment of the E2 ubiquitin-conjugating enzyme facilitating ubiquitin conjugation 26, 27 . Inhibition of neddylation hence leads to reduced protein degradation via reduced ubiquitination and targeting to the proteasome, while proteasome activity itself stays intact. MLN4924 (Pevonedistat®) is the first-in-class inhibitor of this process, targeting the NEDD8 activating enzyme (NAE) 28 . It has shown pre-clinical activity in various solid tumors and hematologic malignancies and is currently in several clinical trials, including a Phase 3 study in hematological malignancies (NCT03268954).
In the present study, we could show that all three inhibitors of the 20S proteolytic core of the proteasome were highly effective in GIST cells. Their effectiveness was not affected by KIT mutational status or sensitivity to imatinib. Mechanistically, the proapoptotic activity of these compounds was mediated by a dual mechanism identical to bortezomib that resulted in upregulation of histone H2AX and transcriptional inhibition of KIT. Of note, delanzomib was the most effective compound tested. By contrast, the DUB inhibitor b-AP15 and the NEDD8 activating enzyme inhibitor MLN4924 had a substantially lesser effect on cell proliferation and induction of apoptosis. In summary, targeting the proteolytic 20S core unit of the proteasome in GIST could be a promising therapeutic strategy in TKI-resistant GISTs.
RESULTS

The second-generation inhibitors of the 20S proteasome carfilzomib, ixazomib and delanzomib effectively induce apoptosis and cell cycle arrest in GIST cells
To determine whether carfilzomib, ixazomib and delanzomib have an effect on GIST cell viability and/or apoptosis, IM-sensitive (GIST882, GIST-T1) and IM-resistant (GIST48, GIST430) GIST cell lines were treated with increasing concentrations covering a 100,000-fold concentration range (0.1 nM -10.0 μM). Cell viability and caspase 3/7 activity were measured using luminescence-based assays ( Fig. 1A, B ; Suppl. Methods).
All three compounds were highly effective with IC 50 s as low as 9 nM (Table 1A) . Of note, delanzomib was the most potent compound (IC 50 s of 9-36 nM), whereas carfilzomib and ixazomib were approximately one order of magnitude less effective (IC 50 s of 67-1679 nM and 41-175 nM, respectively; Table 1A ). Importantly, drug response was independent of KIT mutational status and sensitivity to imatinib. In fact, IM-resistant cells had an overall lower IC 50 for all drugs than IM-sensitive cells.
To biochemically assess tumor cell responses to delanzomib, carfilzomib and ixazomib, we evaluated markers of apoptosis and cell cycle regulation by immunoblot analysis ( Taken together, the second-generation inhibitors of the 20S proteasome delanzomib, carfilzomib and ixazomib showed significant cytotoxic activity in GIST cells, which was independent of the KIT mutational status and hence imatinib sensitivity.
Delanzomib was the most effective of the three compounds tested.
The ability to inhibit the activity of the proteasome and induce accumulation of ubiquitinated proteins correlates with GIST cell cytotoxicity
Delanzomib, carfilzomib and ixazomib predominantly inhibit the chymotrypsin-like activity of the 20S proteasome in multiple myeloma cells 13, 14, 16, 18, 19, 29, 30 . To correlate 20S proteasome inhibitory activity with their cytotoxicity in GIST cells, we measured the chymotrypsin-like activity of the 20S proteasome in a luminescence-based assay using Suc-LLVY-(succinyl-leucine-leucine-valine-tyrosine-)aminoluciferin as a substrate. While all three proteasome inhibitors strongly inhibited the proteasome, delanzomib was most effective, correlating with the compounds' ability to induce apoptosis (EC 50 s of 5-13 nM, Table 1B ). As before, no significant difference between IM-sensitive and IM-resistant GIST cells was seen. Interestingly, carfilzomib and ixazomib showed stronger proteasome inhibition capacity than delanzomib in the lower concentration range when treating IMsensitive GIST882 and GIST-T1 cells ( Fig. 2A ). Together, our results indicate that the potency of proteasome inhibition indeed correlates with cytotoxic efficacy in GIST cells 
Inhibition of the USP14/UCHL5 deubiquitinating enzymes or the NEDD8 activating enzyme (NAE) have a lower pro-apoptotic activity in GIST cells when compared to 20S inhibitors
Having shown that delanzomib, carfilzomib and ixazomib have activity against GIST cells, we tested whether the cytotoxic effect is 20S proteasome inhibitor-specific or whether inhibition of protein degradation by targeting regulators of the ubiquitinproteasome pathway has the same effect. b-AP15 is a deubiquitinase enzyme (DUB) inhibitor that has shown pre-clinical activity 23, 24 . It interferes with ubiquitin cleavage from proteasome-targeted proteins at the 19S regulatory particle of the 26S proteasome, thereby leading to a functional shutdown of the proteasome 3, 20 . Treatment of GIST cells with increasing concentrations of b-AP15 only resulted in a significant reduction in cell viability or increase of apoptosis at very high concentrations (1 μM and higher) as determined by luminescence-based assays (Fig. 3A , B, Suppl. Fig. 4A ). IC 50 s ranged from 0.5 μM and 1.2 μM in IM-resistant cells (GIST48 and GIST430, respectively) to over 8x10 18 μM in IM-sensitive cells (GIST882 ; Table 1C ).
As expected, immunoblot analysis paralleled these results ( Fig. 3B ). While b-AP15 did lead to the accumulation of ubiquitinated proteins, concentrations of 1.0 μM or higher were needed to achieve this effect ( Fig. 3C ).
We then tested the NEDD8 activating enzyme (NAE) inhibitor MLN4924 for its effect on GIST cells. Neddylation is an important regulatory process of the proteolytic machinery 25 . It is critical for the recruitment of the E2 ubiquitin-conjugating enzyme to the E3 ligase complex, thereby facilitating ubiquitin conjugation 27 . Inhibition of neddylation therefore inhibits protein degradation by reducing ubiquitination and hence targeting to the proteasome while leaving proteasome function intact. Treatment of GIST cells with increasing concentrations of MLN4924 showed reduction of cellular proliferation starting at 0.1 μM but did not lead to substantial apoptotic activity in luminescence-based assays ( Fig. 3D ). IC 50 s ranged from 7.3 μM to 461 μM (Table 1C) , favoring IM-resistant cell lines.
Results were paralleled on the molecular level by immunoblot analysis (Fig. 3E , Suppl. 
Delanzomib, carfilzomib and ixazomib induce GIST cell death by upregulation of H2AX and transcriptional downregulation of KIT
Having shown that the 20S proteasome inhibitors delanzomib, carfilzomib and ixazomib have substantial activity in GIST, we set out to determine the mechanism of action of these compounds. As reported in an earlier study by our group, the prototype proteasome inhibitor bortezomib has a dual mechanism of action in GIST through upregulation of the pro-apoptotic histone H2AX and inhibition of transcription resulting in a dramatic loss of KIT expression 5 .
We therefore tested whether delanzomib, carfilzomib and ixazomib have a similar mechanism of action. Indeed, when analyzing H2AX levels by immunoblotting, we found that both phosphorylated and total histone H2AX protein expression increased in a doseand time-dependent manner ( Fig. 4A Fig. 5C ). Carfilzomib and ixazomib had a similar effect (Suppl. Fig. 6E , F).
Transcriptional inhibition after delanzomib treatment was time-dependent over the course of 72 hours. Relocalization of CBP into nuclear foci starts to become apparent at 24 hours, and nuclear protein expression is increasingly lost over the course of the next 48 hours (Suppl. Fig. 7 ). These results correlate well with our immunoblotting data shown in Fig. 4 .
While the global transcriptional downregulation that is observed could be worrisome for non-specific toxicity of the compounds tested here, carfilzomib and ixazomib as well as bortezomib are already FDA-approved. The fact that these drugs are safely used in the clinic, therefore speaks against a major impact in patients.
Interestingly, treatment with the DUB inhibitor b-AP15 and the NAE inhibitor MLN4924 also led to increased phosphorylated and total H2AX levels as well as a reduction of total and phosphorylated KIT ( Fig. 3B , E; Suppl. Fig. 4 ). It is of note, that this effect was only seen at the same high drug concentrations that led to an apoptotic response. This is especially striking in case of MLN4924, because its ability to modulate ubiquitination levels and induce cell cycle exit requires much lower drug concentrations ( Fig. 3E, F) .
Taken together, the pro-apoptotic effect of all compounds targeting the ubiquitin proteasome machinery tested in our study includes a dual mechanism of action resulting in increased levels of soluble histone H2AX and global transcriptional inhibition leading to loss of KIT expression in GIST cells. Nevertheless, there are vast differences in their efficacy with inhibitors of the 20S catalytic core being the most potent compounds. In addition, MLN4924 shows a disconnect between its pro-apoptotic and cell cycle inhibitory function, the latter of which correlated with the drug's ability to modulate protein ubiquitination.
Delanzomib has in vivo antitumor activity in GIST xenografts
Since delanzomib was the strongest inducer of GIST cell death, we next tested its Furthermore, delanzomib resulted in significant tumor reduction comparable to imatinib treatment in the IM-sensitive patient-derived UZLX-GIST1 model over the course of three weeks (Fig. 5A; Suppl. Fig. 8B) 31 . Tumor reduction after delanzomib was accompanied by a marked histopathologic response, and more than 60% of the responses were of grade 3 or higher (Fig. 5B ). Response to delanzomib most prominently resulted in large areas of central necrosis, whereas control imatinib treatment rather led to myxoid degeneration, similar to what is seen in clinical imatinib-treated tumor samples 32 .
Furthermore, treatment with delanzomib caused a highly significant reduction of proliferation, which was equivalent to imatinib treatment (Fig. 5B ). This is exemplified both The changes described above were also reflected when assessing the response of UZLX-GIST1 to delanzomib (24 h) by immunoblotting ( Fig. 5C ). While both imatiniband delanzomib-treated xenografts exhibited reduced cyclin A levels and increased expression of p27 Kip1 indicating cell cycle arrest, only the delanzomib-treated xenografts showed detectable PARP cleavage. Importantly, delanzomib-treated xenografts also show a downregulation of total KIT protein expression, as would be expected from our in vitro data (Fig. 4) . Interestingly, a moderate downregulation of KIT resulted in a complete loss of KIT activation. Results were very much comparable to the UZLX-GIST1 bolus treatment as both models already showed drastic changes with respect to induction of apoptosis (PARP cleavage) and reduced cellular proliferation (decreased cyclin A and increased p27 Kip1 levels in UZLX-GIST1 and decreased Ki-67 expression in UZLX-GIST9) after a single bolus of delanzomib and a short follow-up.
We also tested delanzomib over the course of three weeks in the IM-resistant GIST430 xenograft, where it likewise led to significant histopathologic changes (Fig. 5D ).
Sixty percent of the tumors showed a histopathologic response grade of 2 or higher (Suppl. Fig. 8C ). Furthermore, treatment with delanzomib caused a highly significant reduction of proliferation, exemplified by the decrease of pH3-positive cells (from 94/10 HPF in controls to 22.5/10 HPF; Fig. 5E; Suppl. Fig. 8D ) as well as tumor reduction over time (Suppl. Fig. 8E ).
Taken together, delanzomib has significant activity in GIST xenografts, including IM-resistant models.
DISCUSSION
Although GISTs can be successfully treated with tyrosine kinase inhibitors that target KIT, the majority of patients develop resistance to these drugs, mostly through secondary KIT mutations. Importantly, these resistance mutations can show significant intertumoral and intratumoral heterogeneity while at the same time conferring sensitivity to different second-or third-line kinase inhibitors. Therefore, therapeutically targeting KIT in a mutation-independent manner is an intriguing strategy.
In the present study, we show that inhibitors of the proteolytic machinery are highly effective in GIST cells and that their mechanism of action is independent of KIT mutational status or sensitivity to imatinib. Apoptosis is induced through upregulation of the proapoptotic histone H2AX as well as transcriptional downregulation of KIT, a mechanism previously described by our group for the first-in-class proteasome inhibitor bortezomib [5] [6] [7] . Notably, all tested compounds share this mechanism, regardless of whether they target the 20S proteolytic core of the proteasome or not. The shared transcriptional downregulation of KIT raises the possibility that it could be the result of increased H2AX levels, especially in light of the fact that non-chromatin-bound H2AX can lead to transcriptional inhibition 6 . However, we have shown previously that siRNA-mediated knockdown of H2AX did not completely rescue bortezomib-induced KIT transcriptional downregulation, indicating that additional mechanisms are involved 6 . It is well-known that the proteasome has an important role in transcription initiation 35, 36 . Transcriptional activation domains of many transcription factors, including ETV1, a main transcription factor of KIT in the GIST/interstitial cell of Cajal lineage 37 , often overlap with degrons 35 , indicating that their degradation is crucial for transcriptional activation. Similarly, Sp1 is an important transcription factor involved in the regulation of KIT 38 , and bortezomib has recently been shown to target the specific protein (Sp) family in cancer cells 39 . It therefore seems likely that inhibition of the proteasome directly affects ongoing transcription at the transcription factor level and contributes to the observed transcriptional downregulation of
KIT.
Although all compounds showed some effect in GIST cells, vast differences in drug efficacy were seen, ranging over three orders of magnitude. Compounds that inhibit the 20S catalytic core of the proteasome (delanzomib, carfilzomib and ixazomib), like bortezomib, stood out as the most potent compounds. Importantly, these secondgeneration 20S inhibitors have better pharmacologic properties than bortezomib, including an oral route of administration and less toxicity, which warrant their pre-clinical examination without formally determining the clinical utility of bortezomib 15, 16, 19, 30 .
Despite being the most active compounds in our study, not all 20S inhibitors were equally effective in GIST cells. In fact, the activity of one compound, delanzomib, was one order of magnitude higher than that of carfilzomib and ixazomib. Delanzomib's IC 50 was in the low nanomolar range, largely identical to that of bortezomib. Of note, the reason for the superior efficacy of delanzomib does not seem to lie in a structural similarity to bortezomib or its proteasome binding dynamics: Ixazomib -and not delanzomib -is a direct derivative of bortezomib 16, 30 , and both delanzomib and ixazomib reversibly inhibit the proteasome, whereas carfilzomib, the least effective 20S inhibitor in our study, inhibits the proteasome irreversibly [13] [14] [15] [16] 18, 19 . Our studies do however point to a similar capability of delanzomib and bortezomib to inhibit the β5 chymotrypsin-like subunit of the proteasome (Fig. 2) . In addition, it has recently become clear that co-inhibiting the caspase-like subunit of the proteasome in addition to the chymotrypsin-like subunit increases the ability of proteasome inhibitors to inhibit protein breakdown and enhances their antineoplastic activity 40 . Interestingly, both delanzomib and bortezomib potently inhibit the β1 caspase-like subunit, while carfilzomib and ixazomib do not (15, 36) .
Together, our results indicate that the superior activity of delanzomib is likely mediated through a stronger β5 chymotrypsin-like subunit inhibition and its additional ability to inhibit the β1 caspase-like subunit of the proteasome.
Based on the preclinical results of the compounds tested in our study, delanzomib holds most promise to be effective in the clinical setting for GIST patients. Two early phase clinical trials testing delanzomib in multiple myeloma and solid tumors indeed reported that delanzomib treatment was feasible 20, 41 . Importantly, no neurotoxicity, the most severe adverse effect of bortezomib, was reported. While a few partial responses were seen, however, the best result for most delanzomib-treated patients was stable disease 20, 41 .
Due to the unexpectedly low efficacy, further development of delanzomib for multiple myeloma was discontinued 20 .The future of delanzomib as a treatment for GIST is therefore unclear. Nevertheless, testing other 20S proteasome inhibitors could be worthwhile. One possibility could be ixazomib, which has recently been FDA-approved and was the second-most effective drug in our study. Importantly, ixazomib is an orally available drug and would therefore be well-accepted in a patient population that is not otherwise acquainted with intravenously administered medications 16 . In addition, thirdgeneration compounds have become available since we began our study. Especially marizomib (salinosporamide A; Triphase/Celgene), could be of interest because of its ability to inhibit the β1 caspase-like and β2 trypsin-like subunit in addition to the β5 chymotrypsin-like subunit of the proteasome 42 . As outlined above, this feature seems to be advantageous to ensure a high cytotoxic activity in GIST cells. Marizomib is orally administered and is currently in late phase clinical trials for multiple myeloma, glioma and solid tumors. Another strategy could be to use proteasome inhibitors in combination with other agents, e.g. imatinib. Although preliminary results from our laboratory exploring a combination of imatinib and bortezomib did not show clear synergistic effects, alternative administration regimens, such as drug sequencing, could be explored 43 . Combinations with other agents than imatinib might also be promising. For example, recent strategies combining proteasome inhibitors with other drugs for the treatment of multiple myeloma include AKT/mTOR inhibitors as bortezomib has been shown to increase AKT activation in multiple myeloma cells 44 .
Further studies will be needed to delineate why compounds that target other regulators of the proteolytic machinery have a significantly lower efficacy in GIST cells than 20S inhibitors. The DUB inhibitor b-AP15 clearly had a lower ability to induce the accumulation of poly-ubiquitinated proteins and H2AX upregulation as well as transcriptional inhibition of KIT. Of note, substantially higher concentrations were also needed to induce ubiquitination in the original report using HCT 116 cells 21 . The in vivo efficacy of this compound will therefore depend on its bioavailability and whether it will be feasible to achieve necessary serum levels paired with acceptable toxicity. No clinical trial with b-AP15 has been initiated to this date, but a phase I/II clinical trial to test a derivative, VLX1570 45 , was initiated in 2015 (NCT02372240) and terminated in 2018 due to doselimiting toxicity (clinicaltrials.gov/ct2/show/NCT02372240).
Our results for the NAE inhibitor MLN4924 are more complex. As mentioned above, this compound inhibits a regulatory mechanism that is critical for facilitating ubiquitin conjugation 25 resulting in decreased ubiquitination and limited protein targeting to the 26S proteasome 26, 27 . The function of the proteasome itself stays intact. MLN4924 exhibited a strong cell cycle inhibitory effect in GIST cells, which correlated well with the expected reduction of ubiquitin-conjugated proteins. The particular effect on the cell cycle can be explained by the fact that neddylation has been specifically implicated in modulating activity of cullin-RING E3 ligases, which control the turnover of cell cycleregulating proteins, such as p27 Kip1 27, 28 . It is not that clear why apoptosis is only induced at much higher concentrations of MLN4924, although it did correlate with increased levels of histone H2AX and a decrease in KIT expression, similar to what was seen for the other compounds tested in our study. Although seemingly counterintuitive, both effects can be explained by MLN4924's mechanism of action. As described above, an increase in H2AX levels likely results from decreased degradation due to limited ubiquitination and targeting towards the proteasome. The decrease in KIT expression levels that we observed at high MLN4924 concentrations is likely due to transcriptional inhibition. As mentioned above, it has recently become clear that the ongoing activity of transcriptional activators is dependent on their ubiquitination in addition to the proteolytic capacity of the proteasome 46 . In line with this, MLN4924 has been shown to reduce RNA pol II occupancy at DNA 47 .
MLN4924 has moved forward into several clinical studies 48, 49 . Nevertheless, the maximal serum concentrations achieved in these trials were lower than the clinically meaningful dose for GIST patients and confirms that MLN4924 is not a medication to move forward in this entity.
Unfortunately, many preclinical studies never reach clinical success. While the ultimate significance of proteasome inhibitors for the treatment of patients with GIST is difficult to estimate, the fact that our in vitro and in vivo results are similar to what has been reported in multiple myeloma models is promising. For example, treatment of bortezomibsensitive multiple myeloma (MM) cell lines with delanzomib and bortezomib at concentrations comparable to what we used in our study had a similar effect with respect to the accumulation of ubiquitinated proteins 18 . Another important question for preclinical studies is whether the concentration at which the biologic effects occur are achievable in the serum. Delanzomib serum concentrations for multiple myeloma, for example, while lower than the calculated effective serum concentration needed to treat GIST patients, showed high peak concentrations after initial administration with a rapid distribution into the extra-vascular space 41 . Paired with a prolonged elimination phase and a mean halflife of 62 hours, drug concentrations in the tumor could therefore be sufficient for exerting a biological effect. Similarly, our preclinical data for ixazomib are not that different from what has been reported for myeloma models 30 . On the other hand, it might be difficult to achieve effective serum concentrations of carfilzomib in the patient setting.
In summary, we have shown that inhibitors of the ubiquitin-proteasome machinery, especially those that inhibit the 20S proteolytic core, have therapeutic activity in imatinibsensitive and imatinib-resistant GIST model systems. Clinical studies are encouraged. 
MATERIALS AND METHODS
Cell culture and inhibitor treatments
26S proteasome activity assay
The chymotrypsin-like activity of the proteasome after treatment with the above- 13 mg/kg was tested in myeloma models 18, 54 . Our selected dose of 8 mg/kg was at the low end of the spectrum for myeloma studies and should hence well translate into the human setting. Tumor volume, weight and general health of the mice were recorded 52 .
After the mice were sacrificed, tumors were excised and divided for fresh frozen samples and histopathologic examination. Histopathologic grading of the response to the compounds was based on the microscopic amount of necrosis, myxoid degeneration or fibrosis with grade 1 representing a minimal response (0-10%) and grade 4 representing a maximal response (>90%) 55 .
Statistics
Statistical significance was assessed using Student's t test for independent samples. P values ≤0.05 were considered significant. (E) Immunohistochemical staining for phosphorylated histone H3 S10 in GIST430 xenografts treated with delanzomib or placebo control. Table 1 . IC 50 
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